Drugs / Lilly Glucagon
Lilly Glucagon
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01972152 | Oct 2013 → Feb 2014 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03439072 | Jan → Apr 2018 | hypoglycemia, type 1 diabetes mellitus | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02701257 | Mar 2016 → May 2018 | type 1 diabetes mellitus | Massachusetts General Hospital | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02403648 Comparator | Nov 2014 → Mar 2015 | hypoglycemia | Biodel | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lilly Glucagon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01972152 ↗ |
| Known as | glucagon | “glucagon” NCT02701257 ↗ |
| Known as | glucagon for injection (rDNA origin) | “Lilly Glucagon(TM) \[glucagon for injection (rDNA origin)\], single 1 mg SC injection” NCT01972152 ↗ |
| Route | Subcutaneous | “Lilly Glucagon(TM) \[glucagon for injection (rDNA origin)\], single 1 mg SC injection” NCT01972152 ↗ |